Popular

If Nuvilex were to generate its previous results in a late Phase II or Phase III trial, the Company would likely be the oncology treatment story of the year. For those keeping score, Celgene’s lauded drug increased overall survival by 27%, while Nuvilex increased median survival by nearly 100%. The one-year survival rate was increased by 59% for Abraxane and 100% for Nuvilex’s encapsulated cells plus low-dose ifosfamide

Make no mistake. Andam is no small-time CEO. Kenneth E. Andam is a serial entrepreneur who has founded and operated a number of highly successful local and international companies in the technology, mobile payment, social crowd sourcing space, and online applications space, as well as the consumer and energy sectors.

PetroTech is poised to transform the oil and gas industry. The Company’s patented tools could potentially recover hundreds of millions of barrels of oil from primarily depleted oil reservoirs in the U.S., representing a multi-billion dollar revenue opportunity. Plus the pending closing of a JV transaction on huge property in the Bakken may be a major profit center and value proposition.

Recently published studies have indicated reduction in cholesterol levels. The common denominator in both trials is the correlation between green tea consumption and cholesterol reduction, along with overall wellness, a boon for PLPL.

A recent poll published in the May 30, 2013 edition of The New England Journal of Medicine shows that fully 76% of poll participants (the poll results include some doctors from outside the U.S) are in favor of the use of marijuana for medicinal purposes.

Recent prostate cancer studies involving the use of green tea as a method of inhibiting prostate cancer growth demonstrate yet another major clinical market opportunity for Plandaí Biotechnology Inc. (OTCQB – PLPL - $0.54 – Spec Buy)